目的: 分析1990-2019年中国女性卵巢癌发病率、死亡率及伤残调整寿命年(DALY)变化趋势,以期为其防治提供科学依据。方法: 利用全球疾病负担数据库和中国卫生与经济社会发展统计数据库数据,采用估计年变化百分比和95 %可信区间分析中国女性卵巢癌发病率、死亡率和DALY率的变化趋势,分析卵巢癌的归因疾病负担,比较城市和农村卵巢癌年龄标化死亡率,对比不同国别卵巢癌的疾病负担。结果: 1990-2019年中国女性卵巢癌发病率、死亡率、DALY率呈上升趋势,分别增长258.68 %、262.05 %、203.59 %。从45岁以上年龄组开始,疾病负担呈上升趋势,上升趋势最大的三个年龄段分别为≥60岁且≤64岁、≥65岁且≤69岁、≥70岁且≤74岁年龄组。2013-2019年中国城市卵巢癌年龄标化死亡率高于农村,从增幅看,农村标化死亡率增幅大于城市。从国别看,英国、美国、澳大利亚、日本等国卵巢癌疾病负担高于中国,而30年间疾病负担呈下降趋势。结论: 中国女性卵巢癌疾病负担仍不断增加,发病呈年轻化趋势,应针对高危因素减少卵巢癌的发生,加强“三早”防治,以降低卵巢癌的疾病负担。
Objective: To analyze the trend of incidence, mortality, and disability-adjusted life years (DALY) of ovarian cancer in Chinese women from 1990 to 2019, in order to provide a scientific basis for its prevention and treatment. Methods: The global burden of disease database and China health and economic and social development statistical database were used to analyze the trend of incidence, mortality and DALY rate of ovarian cancer in Chinese women by estimated annual percentage change and 95 % confidence interval. The attributable disease burden of ovarian cancer was analyzed. The age-standardized death rates of urban and rural ovarian cancer were compared, and the disease burden of ovarian cancer in different countries was compared. Results: The incidence, mortality, and disability-adjusted life years increased by 258.68 %, 262.05 %, and 203.59 % from 1990 to 2019, respectively. From the age group above 45 years old, the disease burden showed an increasing trend, and the three age groups with the largest increasing trend were ≥60 years old and ≤64 years old, ≥65 years old and ≤69 years old, ≥70 years old and ≤74 years old, respectively. From 2013 to 2019, the age-standardized death rate of ovarian cancer in urban China was higher than that in rural, while the increase of standardized mortality in rural areas was greater than that in urban. From the perspective of countries, the disease burden of ovarian cancer in the UK, the US, Australia, Japan and other countries is higher than that in China, while the disease burden had shown a downward trend in the past 30 years. Conclusion: The disease burden of ovarian cancer is still increasing in Chinese women, and the incidence of ovarian cancer is becoming younger. Therefore, it is necessary to reduce the incidence of ovarian cancer by targeting high-risk factors and strengthening the prevention and treatment of "three early " to reduce the disease burden of ovarian cancer.
[1] Porfyris O, Alexandrou P, Masaoutis C, et al. Ovarian metastasis of renal cell carcinoma: clinical and pathological presentation of a case[J]. Turk J Urol, 2019,45(2): 150-153.
[2] 丁祺, 杨红玉, 常春, 等. 卵巢癌患者外周血miR-204表达变化的临床病理意义及其对Bcl-2、BDNF的调控作用[J]. 中国计划生育和妇产科, 2021, 13(11):37-41.
[3] Torre LA, Trabert B, Desantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(4): 284-296.
[4] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3): 209-249.
[5] 张爽爽, 夏庆民, 郑荣寿, 等. 中国2010年卵巢癌发病与死亡分析[J]. 中国肿瘤, 2016, 25(3):169-173.
[6] Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results [EB/OL]. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
[7] 杨念念, 严亚琼, 龚洁, 等. 中国2003—2007年卵巢癌发病与死亡分析[J]. 中国肿瘤, 2012, 21(6):401-405.
[8] Puente D, López-Jiménez T, Cos-Claramunt X, et al. Metabolic syndrome and risk of cancer: a study protocol of case-control study using data from the Information System for the Development of Research in Primary Care (SIDIAP) in Catalonia[J]. BMJ Open, 2019,9(6): e025365.
[9] 高晨曦, 卢辉, 邓雷, 等. 代谢综合征与高龄女性卵巢癌的相关性[J]. 中国医科大学学报, 2020, 49(9):818-823.
[10] 邵婷, 陈秀玮. 卵巢癌的病因假说及危险因素和流行病学研究进展[J]. 中华临床医师杂志(电子版), 2013, 7(19):8894-8897.
[11] Kim B, Kim HS, Kim S, et al. Adipose stromal cells from visceral and subcutaneous fat facilitate migration of ovarian cancer cells via IL-6/JAK2/STAT3 pathway[J]. Cancer Res Treat, 2017,49(2): 338-349.
[12] Mizushima T, Miyamoto H. The role of androgen receptor signaling in ovarian cancer[J]. Cells, 2019,8(2): 176.
[13] Cho U, Kim B, Kim S, et al. Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-κB activation[J]. Mol Carcinog, 2018,57(2): 235-242.
[14] 彭翔云, 王岚, 李秋萍. 肥胖与卵巢癌的发病与预后[J]. 系统医学, 2019, 4(10):186-188.
